{"nctId":"NCT05378672","briefTitle":"A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D","startDateStruct":{"date":"2023-05-09","type":"ACTUAL"},"conditions":["Hypoglycemia","Type 1 Diabetes"],"count":8,"armGroups":[{"label":"Dasiglucagon 0.6 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dasiglucagon"]},{"label":"Dasiglucagon 0.3 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dasiglucagon"]}],"interventions":[{"name":"Dasiglucagon","otherNames":["Zegalogue, ZP4207"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who are confirmed as having T1D based on medical history and are receiving daily insulin therapy via insulin pump or MDI\n* Body weight greater than 8 kg\n* Child must be \\<6 years of age at the time of screening\n* Further inclusion criteria apply\n\nExclusion Criteria:\n\n* Known or suspected allergy to the IMP or related products\n* Any condition that in the investigators opinion may result in diminished hepatic glycogen stores (e.g., prolonged fasting (more than 24 hours) at Visit 2\n* History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema)\n* History of hypoglycemic events associated with seizures\n* Further exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Plasma Glucose Concentration at 30 Minutes After IMP Injection","description":"Glucose levels were monitored by continuous glucose monitoring and by a plasma glucose analyzer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102.3","spread":"10.72"},{"groupId":"OG001","value":"104.3","spread":"14.47"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Plasma Glucose Concentration at 15 Minutes After IMP Injection","description":"Glucose levels were monitored by continuous glucose monitoring and by a plasma glucose analyzer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":"13.84"},{"groupId":"OG001","value":"53.3","spread":"4.04"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"Treatment-emergence was defined as those adverse events (AEs) that occurred after dosing and those existing AEs that worsened during the study. An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of trial intervention, whether or not considered related to the trial intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the trial intervention.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Received Rescue Intravenous (IV) Glucose Infusion Administration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First IV Glucose Infusion Following Treatment With Dasiglucagon","description":"Time to first IV glucose infusion (minutes) was defined as Time of start of first glucose administration - Time of administration of study medication.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Hyperglycaemia","Vomiting","Lymphadenopathy","Nausea","Hypoglycaemia"]}}}